Rise of prediagnostic molecular profiling in inflammatory bowel disease-can we close the door before the horse has bolted?

Molecular features detectable years before clinical IBD diagnosis suggest a preclinical phase with potential for early intervention.

• Why it matters: Identifying IBD before symptoms appear could enable proactive strategies to prevent disease progression, addressing a critical gap in early diagnosis.
• What they did: Analysis of archived biological samples from large longitudinal cohorts identified increased antimicrobial and autoreactive antibodies, immune protein perturbations, and early tissue injury markers in individuals years before IBD diagnosis.
• The result: These molecular signatures may form scalable biomarker panels for preclinical detection, opening opportunities to intercept IBD before clinical onset.